BWX's second quarter performance reflected robust demand across both its government and commercial nuclear businesses, with revenue growth led by increased activity in commercial nuclear power and aftermarket services. Management pointed to strong operational execution and productivity improvements, particularly in Government Operations, as key contributors. CEO Rex Geveden highlighted the company's “position of strength with exposure across the nuclear value chain,” and noted that the recent sale of the medical business will allow BWX to sharpen its focus on core markets. The company also benefited from progress in its enrichment and advanced nuclear fuel programs, while maintaining stable operating margins.
Is now the time to buy BWXT? Find out in our full research report (it’s free for active Edge members).
BWX (BWXT) Q2 CY2026 Highlights:
- Revenue: $901.6 million vs analyst estimates of $904 million (18% year-on-year growth, in line)
- Adjusted EPS: $1.07 vs analyst estimates of $1.04 (2.7% beat)
- Adjusted EBITDA: $155.5 million vs analyst estimates of $149.5 million (17.2% margin, 4% beat)
- Management raised its full-year Adjusted EPS guidance to $4.75 at the midpoint, a 1.6% increase
- EBITDA guidance for the full year is $667 million at the midpoint, above analyst estimates of $652.9 million
- Operating Margin: 12.7%, in line with the same quarter last year
- Backlog: $8.40 billion at quarter end, up 39.6% year on year
- Market Capitalization: $15.57 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From BWX’s Q2 Earnings Call
- Bob Labick (CJS Securities) asked about the drivers and range of outcomes for the medical business sale. CEO Rex Geveden explained the strategic rationale and CFO Michael Fitzgerald detailed the consideration structure, emphasizing capital redeployment toward core markets.
- Scott Deuschle (Deutsche Bank) inquired about the likelihood and type of upcoming nuclear equipment orders. Geveden described active quoting on both gigawatt-class and small modular reactor projects, noting that utilities are awaiting government-backed deal structures before committing.
- Jeffrey Campbell (Seaport Research Partners) questioned the use of medical sale proceeds. Fitzgerald said priorities include internal capacity investment, M&A aligned with strategy, and potential debt reduction, with no immediate plans for share repurchases.
- Matthew Akers (BNP Paribas) asked about progress and capacity needs for the proposed nuclear-powered battleship. Geveden responded that the project is in early stages and would fit existing reactor lines, but the updated Ford-class procurement cadence is likely to have a greater impact on volume stability.
- Mark Shooter (William Blair) requested clarity on the timeline for TRISO fuel commercialization. Geveden said BWX is waiting for a solid pipeline of customer orders and key government decisions before committing major capital, with potential investment offset by grants and partnerships.
Catalysts in Upcoming Quarters
In the coming quarters, our team will closely monitor (1) progress on new large equipment orders in both the gigawatt-class and small modular reactor categories; (2) the pace and execution of U.S. manufacturing capacity expansion, including site selection for new facilities; and (3) government program milestones, such as shipbuilding cadence changes and enrichment plant development. The integration of PCG and realization of synergies will also be key.
BWX currently trades at $170.00, down from $173.79 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
